

Wenâ''Zhao Zhong

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6662866/publications.pdf>

Version: 2024-02-01

43
papers

1,666
citations

516710

16
h-index

330143

37
g-index

47
all docs

47
docs citations

47
times ranked

1749
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, 805-815.e3.	0.8	12
2	Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study. JTO Clinical and Research Reports, 2022, 3, 100257.	1.1	11
3	Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma. , 2022, 10, e003534.		56
4	Identification of heritable rare variants associated with early-stage lung adenocarcinoma risk. Translational Lung Cancer Research, 2022, 11, 509-522.	2.8	5
5	Intratumoral genetic and immune microenvironmental heterogeneity in <scp>T4N0M0</scp> (diameter≤7Åcm) non-small cell lung cancers. Thoracic Cancer, 2022, , .	1.9	2
6	New Normal for Lung Cancer Clinical Trials Under Coronavirus Disease 2019. Journal of Thoracic Oncology, 2022, 17, 588-591.	1.1	1
7	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-III A (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. Journal of Clinical Oncology, 2021, 39, 713-722.	1.6	159
8	Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. Cancer Treatment and Research Communications, 2021, 26, 100297.	1.7	4
9	Electromagnetic navigation bronchoscopic localization versus percutaneous <scp>CT</scp>-guided localization for thoracoscopic resection of small pulmonary nodules. Thoracic Cancer, 2021, 12, 468-474.	1.9	20
10	Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. Cancer Communications, 2021, 41, 287-302.	9.2	74
11	Watershed analysis of the target pulmonary artery for real-time localization of non-palpable pulmonary nodules. Translational Lung Cancer Research, 2021, 10, 1711-1719.	2.8	4
12	Multimomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. , 2021, 9, e002312.		21
13	Timing and Origins of Local and Distant Metastases in Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1136-1148.	1.1	39
14	Precise resection of multiple pulmonary nodules using a three-dimensional reconstruction model: A case report. Thoracic Cancer, 2021, 12, 970-973.	1.9	3
15	A three-dimensional printing navigational template combined with mixed reality technique for localizing pulmonary nodules. Interactive Cardiovascular and Thoracic Surgery, 2021, 32, 552-559.	1.1	6
16	Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. Nature Communications, 2021, 12, 6450.	12.8	48
17	MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. Experimental Hematology and Oncology, 2021, 10, 52.	5.0	28
18	Genomic Evolution of Lung Cancer Metastasis: Current Status and Perspectives. Cancer Communications, 2021, 41, 1252-1256.	9.2	8

#	ARTICLE	IF	CITATIONS
19	Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers. <i>Annals of Thoracic Surgery</i> , 2020, 109, 856-863.	1.3	10
20	Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. <i>Lung Cancer</i> , 2020, 139, 118-123.	2.0	33
21	<scp>Three-dimensional printed navigational template for localizing small pulmonary nodules: A <scp>case-controlled study. <i>Thoracic Cancer</i> , 2020, 11, 2690-2697.	1.9	5
22	Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020, 12, 5822-5832.	1.4	4
23	Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. <i>EBioMedicine</i> , 2020, 60, 102990.	6.1	95
24	Genomic characteristics and drug screening among organoids derived from <scp>non-small cell</scp> lung cancer patients. <i>Thoracic Cancer</i> , 2020, 11, 2279-2290.	1.9	39
25	Randomized Trial of an Improved Drainage Strategy Versus Routine Chest Tube After Lung Wedge Resection. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1040-1046.	1.3	16
26	Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 3808-3818.	1.5	10
27	ASO Author Reflections: Lung Adenocarcinoma with Accidental Invisible Pleural Dissemination Lesions: Wait-and-See Strategy for Tumors with Indolent Biologic Characteristics. <i>Annals of Surgical Oncology</i> , 2020, 27, 3819-3820.	1.5	0
28	Drainage tube hole suture improvement: Removal-free stitches. <i>Thoracic Cancer</i> , 2019, 10, 1827-1833.	1.9	5
29	Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1912-1923.	1.1	105
30	Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2019, 19, 1051.	2.6	6
31	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2235-2245.	1.6	193
32	The superstars of precision medicine—EGFR inhibitors in adjuvant treatment of lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, E11-E13.	1.4	0
33	Application of indocyanine green fluorescence for precision sublobar resection. <i>Thoracic Cancer</i> , 2019, 10, 624-630.	1.9	21
34	Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer — Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e127.	10.7	2
35	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–III A (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , The, 2018, 19, 139-148.	10.7	436
36	Prophylactic air-extraction strategy after thoracoscopic wedge resection. <i>Thoracic Cancer</i> , 2018, 9, 1406-1412.	1.9	14

#	ARTICLE	IF	CITATIONS
37	Acquired <i>MET</i> Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 4929-4937.	7.0	67
38	Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients. <i>Chinese Journal of Cancer</i> , 2017, 36, 53.	4.9	5
39	The resistance mechanisms and treatment strategies for <i>EGFR</i> -mutant advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 71358-71370.	1.8	51
40	Minimally invasive, multi-disciplinary approach for surgical management of a mediastinal congenital bronchogenic cyst in a 6-month-old infant. <i>Journal of Thoracic Disease</i> , 2017, 9, E743-E747.	1.4	2
41	Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis. <i>Journal of Thoracic Disease</i> , 2015, 7, 1205-12.	1.4	11
42	Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. <i>Journal of Thoracic Disease</i> , 2015, 7, 1181-8.	1.4	17
43	Lung Cancer Treatment Disparities in China: A Question in Need of an Answer. <i>Oncologist</i> , 2014, 19, 1084-1090.	3.7	18